GlassScriptPhysician profile
Catherine E Clingan
NPI 1013498435
$7,101.04
in general payments reported to CMS, 2019-2025
30 companies · $1,076 in 2025
The $1,076 reported for 2025 was more than what 86% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,674 · 2022: $800 · 2023: $345 · 2024: $3,205 · 2025: $1,076.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,530 · Travel and Lodging: $1,806 · Consulting Fee: $200 · Education: $90.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.29 |
| Travel and Lodging | $1,806.37 |
| Consulting Fee | $200.00 |
| Education | $90.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $2,287.10 | 2024 | Inspire |
| Jazz Pharmaceuticals INC. | $1,769.23 | 2021-2024 | |
| Biotronik Nro, INC. | $522.63 | 2025 | Prospera |
| Avadel Cns Pharmaceuticals, LLC | $342.03 | 2024-2025 | Lumryz |
| Axsome Therapeutics, INC. | $249.54 | 2024 | Sunosi, Auvelity |
| Harmony Biosciences LLC | $232.09 | 2021-2024 | |
| Abbvie INC. | $187.35 | 2021-2023 | |
| Eisai INC. | $164.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $144.47 | 2021-2022 | |
| Lilly USA, LLC | $140.78 | 2021-2025 | Zepbound |
| Novo Nordisk INC | $138.08 | 2021 | |
| Spinal Simplicity, LLC | $133.13 | 2025 | Ha Minuteman G3-R |
| Janssen Pharmaceuticals, INC | $124.99 | 2023 | Spravato |
| Amgen INC. | $119.23 | 2021 | |
| Si-Bone, INC. | $95.46 | 2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $73.47 | 2021 | |
| Medtronic, INC. | $53.97 | 2023-2024 | Intellis Adaptivestim |
| Amarin Pharma, INC. | $53.51 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.96 | 2024 | Caplyta |
| Arbor Pharmaceuticals, INC. | $42.88 | 2021 | |
| Collegium Pharmaceutical, INC. | $34.01 | 2022-2023 | Xtampza |
| Astrazeneca Pharmaceuticals LP | $24.43 | 2021 | |
| Bausch Health US, LLC | $18.33 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.00 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.39 | 2023 | Seglentis |
| Averitas Pharma INC. | $16.15 | 2024 | Qutenza |
| Itamar Medical INC | $15.75 | 2021 | |
| Idorsia Pharmaceuticals US INC | $13.99 | 2024 | Quviviq |
| Sanofi-Aventis U.S. LLC | $13.91 | 2021 | |
| Esperion Therapeutics, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Clingan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.